| CAS NO: | 66085-59-4 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| Molecular Weight (MW) | 418.44 |
|---|---|
| Formula | C21H26N2O7 |
| CAS No. | 66085-59-4 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 84 mg/mL (200.7 mM) |
| Water: < 1 mg/mL | |
| Ethanol: 84 mg/mL (200.7 mM) | |
| Other info | Chemical Name: 3-isopropyl 5-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate InChi Key: UIAGMCDKSXEBJQ-UHFFFAOYSA-N InChi Code: InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3 SMILES Code: CC1=C(C(OCCOC)=O)C(C2=CC([N+]([O-])=O)=CC=C2)C(C(OC(C)C)=O)=C(C)N1 |
| Synonyms | BAY E 9736; BAY-E-9736, Nimodipine, Nimotop, Periplum, BAY E 9736, BAYE9736 |
| In Vitro | In vitro activity: Nimodipine decreases both the peak amplitude and the integrated area of the AHP in an age- and concentration-dependent manner. Nimodipine (100 nM) significantly reduces the AHP in aging CA1 neurons. Nimodipine increases excitability in an age- and concentration-dependent manner by decreasing spike frequency accommodation (increasing the number of action potentials during prolonged depolarizing current injection). Nimodipine decreases accommodation only at higher concentrations in young CA1 neurons. Nimodipine decreases the plateau phase of the calcium AP at concentrations as low as 100 nM in aging neurons and 10 mM in young rat neurons. Cell Assay: Nimodipine decreases intracellular free Ca2+,Beclin-1 and autophagy. Target: Calcium Channel Nimodipine is main use is in the prevention of cerebral vasospasm and resultant ischemia, a complication of subarachnoid hemorrhage (a form of cerebral bleed), specifically from ruptured intracranial berry aneurysms irrespective of the patient's post-ictus neurological condition. Its administration begins within 4 days of a subarachnoid hemorrhage and is continued for three weeks. If blood pressure drops by over 5%, dosage is adjusted. There is still controversy regarding the use of intravenous nimodipine on a routine basis . |
|---|---|
| In Vivo | Nimodipine results in reversible, dose-related suppression of the compound action potential of the auditory nerve (CAP; N1-P1), a prolongation of N1 latency at suprathreshold levels, an elevated CAP threshold, a decrease in N1 latency at a constant amplitude measured at CAP threshold, a reduction in cochlear microphonics (CM), and a reduction of the negative summating potential (SP) to a point where it becomes positive. Nimodipine (10 mg/kg, SC), an L-type dihydropyridine Ca2+ channel antagonist, appears to completely block the establishment of conditioning of cocaine's effects, but only partially blocks sensitization to cocaine. Nimodipine (5-20 mg/kg, SC) inhibits in a dose-related manner self-administration both of cocaine and morphine contingent upon a nose-poke response. |
| Animal model | N/A |
| Formulation & Dosage | 5-20 mg/kg, SC |
| References | J Neurophysiol. 1992 Dec;68(6):2100-9; Hear Res. 1990 Jul;46(3):277-87. |
m.cnreagent.com